RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+8.88%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$4.2B
AUM Growth
+$4.2B
(+0.35%)
Cap. Flow
-$163M
Cap. Flow
% of AUM
-3.88%
Top 10 Holdings %
Top 10 Hldgs %
34.34%
Holding
127
New
6
Increased
35
Reduced
17
Closed
3
Top Buys
| 1 |
Humana
HUM
|
$19.5M |
| 2 |
Boston Scientific
BSX
|
$14.5M |
| 3 |
Merus
MRUS
|
$12.6M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$9.71M |
| 5 |
Agilon Health
AGL
|
$6.94M |
Top Sells
Sector Composition
| 1 | Healthcare | 97.2% |
| 2 | Consumer Staples | 1.04% |
| 3 | Industrials | 0.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Lifestance Health
LFST
$2.13B
| $26.5M | 0.63% | 2,900,000 | – | – |
|
52
Rhythm Pharmaceuticals
RYTM
$6.85B
| $26.3M | 0.63% | 1,597,123 | – | – |
|
53
Travere Therapeutics
TVTX
$1.56B
| $23.5M | 0.56% | 1,527,720 +251,070 | +20% | +$3.86M |
|
54
Dynavax Technologies
DVAX
$1.19B
| $23.4M | 0.56% | 1,813,758 | – | – |
|
55
BioMarin Pharmaceuticals
BMRN
$11.2B
| $22.9M | 0.55% | 264,500 | – | – |
|
56
Azenta
AZTA
$1.4B
| $21.9M | 0.52% | 469,900 +38,700 | +9% | +$1.81M |
|
57
Mineralys Therapeutics
MLYS
$1.03B
| $19.9M | 0.47% | 1,167,492 | – | – |
|
|
INZY
58
DELISTED
Inozyme Pharma
INZY
| $19.1M | 0.45% | 3,428,084 +213,184 | +7% | +$1.19M |
|
59
Revolution Medicines
RVMD
$7.1B
| $18.8M | 0.45% | 702,712 | – | – |
|
60
Biomea Fusion
BMEA
$116M
| $18.4M | 0.44% | 836,898 -460,315 | -35% | -$10.1M |
|
61
BioCryst Pharmaceuticals
BCRX
$1.74B
| $17.6M | 0.42% | 2,497,193 +163,108 | +7% | +$1.15M |
|
62
Compass Therapeutics
CMPX
$483M
| $17.5M | 0.42% | 5,513,788 | – | – |
|
63
Disc Medicine
IRON
$2.07B
| $16.1M | 0.38% | 363,468 +50,000 | +16% | +$2.22M |
|
64
Warby Parker
WRBY
$3.2B
| $15.5M | 0.37% | 1,325,000 +25,000 | +2% | +$292K |
|
|
KDNY
65
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $15.2M | 0.36% | 396,280 -111,232 | -22% | -$4.27M |
|
66
Cytokinetics
CYTK
$4.23B
| $14.6M | 0.35% | 447,600 | – | – |
|
|
67
Boston Scientific
BSX
$156B
| $14.5M | 0.34% | +267,500 | New | +$14.5M |
|
68
Celldex Therapeutics
CLDX
$1.47B
| $14.3M | 0.34% | 421,615 +111 | +0% | +$3.77K |
|
69
Collegium Pharmaceutical
COLL
$1.22B
| $14M | 0.33% | 650,000 | – | – |
|
70
Amicus Therapeutics
FOLD
$2.34B
| $13.4M | 0.32% | 1,063,806 | – | – |
|
|
71
Merus
MRUS
$4.98B
| $12.6M | 0.3% | +478,531 | New | +$12.6M |
|
72
Aura Biosciences
AURA
$389M
| $12.6M | 0.3% | 1,019,757 | – | – |
|
73
Health Catalyst
HCAT
$239M
| $11.6M | 0.28% | 929,900 | – | – |
|
74
Mersana Therapeutics
MRSN
$36.5M
| $11.2M | 0.27% | 3,403,133 -700,670 | -17% | -$2.31M |
|
|
EDAP
75
EDAP TMS
EDAP
$84.5M
| $10.9M | 0.26% | 1,186,300 +156,300 | +15% | +$1.44M |
|